Skip to main navigation Skip to search Skip to main content

Copy number variants are ovarian cancer risk alleles at known and novel risk loci

  • Amber A. Devries
  • , Joe Dennis
  • , Jonathan P. Tyrer
  • , Pei Chen Peng
  • , Simon G. Coetzee
  • , Alberto L. Reyes
  • , Jasmine T. Plummer
  • , Brian D. Davis
  • , Stephanie S. Chen
  • , Felipe Segato Dezem
  • , Katja K.H. Aben
  • , Hoda Anton-Culver
  • , Natalia N. Antonenkova
  • , Matthias W. Beckmann
  • , Alicia Beeghly-Fadiel
  • , Andrew Berchuck
  • , Natalia V. Bogdanova
  • , Nadja Bogdanova-Markov
  • , James D. Brenton
  • , Ralf Butzow
  • Ian Campbell, Jenny Chang-Claude, Georgia Chenevix-Trench, Linda S. Cook, Anna Defazio, Jennifer A. Doherty, Thilo Dork, Diana M. Eccles, A. Heather Eliassen, Peter A. Fasching, Renee T. Fortner, Graham G. Giles, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Niclas Hakansson, Michelle A.T. Hildebrandt, Chad Huff, David G. Huntsman, Allan Jensen, Siddhartha Kar, Beth Y. Karlan, Elza K. Khusnutdinova, Lambertus A. Kiemeney, Susanne K. Kjaer, Jolanta Kupryjanczyk, Marilyne Labrie, Diether Lambrechts, Nhu D. Le, Jan Lubinski, Taymaa May, Usha Menon, Roger L. Milne, Francesmary Modugno, Alvaro N. Monteiro, Kirsten B. Moysich, Kunle Odunsi, Hakan Olsson, Celeste L. Pearce, Tanja Pejovic, Susan J. Ramus, Elio Riboli, Marjorie J. Riggan, Isabelle Romieu, Dale P. Sandler, Joellen M. Schildkraut, V. Wendy Setiawan, Weiva Sieh, Honglin Song, Rebecca Sutphen, Kathryn L. Terry, Pamela J. Thompson, Linda Titus, Shelley S. Tworoger, Els Van Nieuwenhuysen, Digna Velez Edwards, Penelope M. Webb, Nicolas Wentzensen, Alice S. Whittemore, Alicja Wolk, Anna H. Wu, Argyrios Ziogas, Matthew L. Freedman, Kate Lawrenson, Paul D.P. Pharoah, Douglas F. Easton, Simon A. Gayther, Michelle R. Jones
  • Cedars-Sinai Medical Center
  • University of Cambridge
  • Radboud University Nijmegen
  • Netherlands Comprehensive Cancer Organization
  • University of California at Irvine
  • Settlement of Lesnoy-2
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Vanderbilt University
  • Duke University
  • Hannover Medical School
  • University of Münster
  • Cancer Research UK Cambridge Institute
  • Helsinki University Hospital
  • Peter Maccallum Cancer Centre
  • University of Melbourne
  • German Cancer Research Center
  • University of Hamburg
  • Queensland Institute of Medical Research
  • Colorado School of Public Health
  • University of Calgary
  • Westmead Institute for Medical Research
  • Westmead Hospital
  • The University of Sydney
  • University of Utah
  • University of Southampton
  • Brigham and Women’s Hospital
  • Harvard University
  • University of California at Los Angeles
  • Cancer Council Victoria
  • Monash University
  • Mayo Clinic Rochester, MN
  • Pomeranian Medical University in Szczecin
  • Karolinska Institutet
  • University of Texas MD Anderson Cancer Center
  • University of British Columbia
  • Provincial Health Services Authority
  • Danish Cancer Society
  • University of Bristol
  • Russian Academy of Sciences
  • St. Petersburg State University
  • University of Copenhagen
  • Maria Sklodowska-Curie Institute of Oncology
  • Oregon Health and Science University
  • Flanders Institute for Biotechnology
  • KU Leuven
  • University Health Network
  • University College London
  • University of Pittsburgh
  • Moffitt Cancer Center
  • The University of Chicago
  • Lund University
  • University of Michigan, Ann Arbor
  • University of Southern California
  • University of New South Wales
  • Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre
  • Imperial College London
  • International Agency for Research on Cancer
  • National Institutes of Health
  • Emory University
  • Icahn School of Medicine at Mount Sinai
  • University of South Florida
  • Public Health
  • Stanford University
  • Uppsala University
  • Dana-Farber Cancer Institute

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background: Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort. Methods: Single nucleotide polymorphism array data from 13071 EOC cases and 17306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types. Results: We identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P <. 001) were identified for rare CNVs. Risk-associated CNVs were enriched (P <. 05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types. Conclusions: CNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.

Original languageEnglish
Pages (from-to)1533-1544
Number of pages12
JournalJournal of the National Cancer Institute
Volume114
Issue number11
DOIs
StatePublished - Nov 1 2022

Fingerprint

Dive into the research topics of 'Copy number variants are ovarian cancer risk alleles at known and novel risk loci'. Together they form a unique fingerprint.

Cite this